Conversely, prostate‐specific membrane antigen (PSMA) targeted ligands with high affinity for cell surface PSMA over‐expressed in prostate cancer cells, tend to be antagonists and, thus, block the action of the cell surface antigen. Here, FOLH1 is linked to prostate carcinoma.